Indication
Drug-induced Acneiform Eruption
1 clinical trial
1 product
Clinical trial
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor InhibitorsStatus: Recruiting, Estimated PCD: 2024-12-30
Product
HT-001